Sight Sciences Inc

SGHT remains in a Stage 2 advancing phase, underpinned by an active Lockout Rally that has driven price above the 9 and 21 EMAs on rising volume. The medium-term bias is bullish, supported by a HH/HL sequence off the March low, while the long-term trend stays intact. Short-term execution is favorable now under the Lockout Rally override, so participation at shallow pullbacks into the EMAs aligns with continuation dynamics.

• ↑Q1 2026 revenue $19.7M, up 13% YoY across glaucoma and dry eye.
• ↑Raised 2026 revenue guidance to $83–89M, implying 7–15% growth.
• ↓Negative earnings yield and profitability factors signal weak returns.